Company intelligence / Profile preview

Hangzhou Sanyintai Pharmaceutical Technology

Hangzhou, Zhejiang Sheng/Zhejiang Province, China

Ownership: Private
Development stage: Preclinical

Overview

Hangzhou Sanyintai Pharmaceutical Technology is a private Chinese pharmaceutical company focused on small molecule drug development. As of early 2025, it has two lead clinical-stage assets in Phase 1 trials targeting HER2 and BTK for oncology and hematology indications[1][2]. No published clinical results are available.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

BTK inhibitor compounds

Pre-clinical

Indications: Autoimmune diseases, Cancer, Inflammatory diseases, Thromboembolic diseases

Beyond the preview

Go deeper on Hangzhou Sanyintai Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Sanyintai Pharmaceutical Technology.

Explore the full profile